Insmed (INSM)
Insmed Revenue Growth
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
INSM Revenue Growth Range, Past 5 Years
| Minimum | -75.93% | Sep 2011 |
| Maximum | 983.3% | Jun 2007 |
| Average | 94.38% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these INSM related companies
INSM News
$INSM 200 Day SMA Cross - Price crossed above 200 day SMA (4.0927). Confirmed by volume.
about 21 days ago by TradeIdeasQuant
about 21 days ago by TradeIdeasQuant
Listen to $INSM Q1 2012 earnings call - live at 08:30 AM, ondemand after - http://stks.co/3iQw
about 21 days ago by earningscast
about 21 days ago by earningscast
$insm took a few short here..might crack into the close http://stks.co/3hmM
about 22 days ago by kunal00
about 22 days ago by kunal00
started into small short on $INSM 4.89 will add in the low 5's target 4
about 22 days ago by LincolnList
about 22 days ago by LincolnList
Insmed $INSM Says Clinical Hold on ARIKACE in CF Patients Lifted
about 22 days ago by Street_Insider
about 22 days ago by Street_Insider
$INSM filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3HoE
about 49 days ago by MarketBrief
about 49 days ago by MarketBrief
Listen to $INSM Q4 2011 earnings call - live at 08:30 AM, ondemand after - http://stks.co/2oMs
about 77 days ago by earningscast
about 77 days ago by earningscast
Insmed (INSM) Commences ARIKACE Phase 2 in NTM Lung Disease Patients, Phase 3 in CF Patients w/ Pa
Feb 10, 8:05AM Street Insider
Feb 10, 8:05AM Street Insider
steppin out to meet tax man.....have order waitin on $INSM if it goes low enough
about 126 days ago by highgrowthfinancial
about 126 days ago by highgrowthfinancial
$INSM could of had 3k @$3.74, stubbornly left bid @$3.73...didn't fill 1 share.WTF! finished strong. will take another look tues
about 127 days ago by highgrowthfinancial
about 127 days ago by highgrowthfinancial
Feuerstein: Insmed Remove on Clinical Hold is "OK", But Still A lot of Overhanging Risk
Jan 20, 8:57AM Benzinga
Jan 20, 8:57AM Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| INSM | 2.97 | -0.01 | -0.34% | 74.08M |
| HBOS | 12.26 | -0.09 | -0.73% | |
| HBNC | 25.10 | -0.15 | -0.59% | 125.49M |
| HBIO | 3.60 | +0.00 | +0.00% | 103.50M |
| HBI | 27.89 | +0.84 | +3.11% | 2.639B |
| HBHC | 30.48 | +0.76 | +2.56% | 2.549B |
| HBC | 40.37 | +0.14 | +0.35% | |
| HBAN | 6.64 | +0.18 | +2.79% | 5.593B |
| GWR | 51.44 | -0.22 | -0.43% | 2.194B |
| GVP | 2.29 | -0.07 | -2.97% | 43.33M |
